I

Imexpharm Corp
VN:IMP

Watchlist Manager
Imexpharm Corp
VN:IMP
Watchlist
Price: 52 100 VND -0.76% Market Closed
Market Cap: 8T VND

Relative Value

The Relative Value of one IMP stock under the Base Case scenario is hidden VND. Compared to the current market price of 52 100 VND, Imexpharm Corp is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IMP Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
15
vs Industry
36
Median 3Y
2.5
Median 5Y
1.4
Industry
2.6
Forward
3.1
vs History
15
vs Industry
20
Median 3Y
21.1
Median 5Y
11
Industry
21.4
Forward
23.1
vs History
vs Industry
14
Median 3Y
5.7
Median 5Y
7.8
Industry
16.4
vs History
4
vs Industry
12
Median 3Y
19.3
Median 5Y
13.7
Industry
22.8
vs History
9
vs Industry
23
Median 3Y
2.5
Median 5Y
1.1
Industry
2.2
vs History
11
vs Industry
37
Median 3Y
2.4
Median 5Y
1.4
Industry
2.9
Forward
3.1
vs History
17
vs Industry
27
Median 3Y
6.5
Median 5Y
3.5
Industry
5.5
vs History
17
vs Industry
27
Median 3Y
11.5
Median 5Y
6.2
Industry
13
Forward
13.4
vs History
20
vs Industry
25
Median 3Y
15.1
Median 5Y
7.8
Industry
16.5
Forward
17
vs History
vs Industry
14
Median 3Y
4.7
Median 5Y
7.7
Industry
15.6
vs History
vs Industry
8
Median 3Y
4.9
Median 5Y
7.3
Industry
18.7
vs History
14
vs Industry
24
Median 3Y
2.3
Median 5Y
1
Industry
1.9

Multiples Across Competitors

IMP Competitors Multiples
Imexpharm Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
VN
Imexpharm Corp
VN:IMP
8T VND 3.3 25.1 14.3 17.6
US
Eli Lilly and Co
NYSE:LLY
997.6B USD 16.8 54.2 36.4 39
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
494.8B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
263.6B CHF 4.3 28 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
218.4B GBP 5.1 31.5 109.5 160.2
CH
Novartis AG
SIX:NOVN
214.5B CHF 4.8 18.8 11.9 15.4
US
Merck & Co Inc
NYSE:MRK
270.7B USD 4.2 14.2 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.7 11 12.7
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
146.1B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
VN
I
Imexpharm Corp
VN:IMP
Average P/E: 24.7
25.1
15%
1.7
US
Eli Lilly and Co
NYSE:LLY
54.2
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
28
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.5
37%
0.9
CH
Novartis AG
SIX:NOVN
18.8
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
VN
I
Imexpharm Corp
VN:IMP
Average EV/EBITDA: 401.2
14.3
15%
1
US
Eli Lilly and Co
NYSE:LLY
36.4
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
109.5
10%
10.9
CH
Novartis AG
SIX:NOVN
11.9
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
VN
I
Imexpharm Corp
VN:IMP
Average EV/EBIT: 1 714
17.6
18%
1
US
Eli Lilly and Co
NYSE:LLY
39
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
160.2
23%
7
CH
Novartis AG
SIX:NOVN
15.4
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5